-
Mashup Score: 11Cancer Trial Results - 6 month(s) ago
Clin Larvol | Cancer Trial Results
Source: clin.larvol.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0AQUILA - A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma - 6 month(s) ago
Check this out – AQUILA – A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
Source: clin.larvol.comCategories: General Medicine News, Hem/OncsTweet-
@majorajay @NEJM Our current CLIN rating is “positive” (not practice informing or changing). @sweta_agrw https://t.co/DuzyzEDw7F https://t.co/7GkriBCwm0
-
-
Mashup Score: 7Cancer Trial Results - 6 month(s) ago
Clin Larvol | Cancer Trial Results
Source: clin.larvol.comCategories: General Medicine News, Hem/OncsTweet-
@mtmdphd @grpetersen1 @bdermanmd @HadidiSamer @jmikhaelmd @MyelomaTeacher @RahulBanerjeeMD @rajshekharucms @szusmani @End_myeloma @bhemato @MeeraMohanMD @myelomaMD @VincentRK @CyclingDoctor @Amyloid_Planet @MayoMyeloma OncoBuzz so far (https://t.co/F0b1m8s1Hw) https://t.co/zrlfbQEwQT
-
-
Mashup Score: 20ASCO 2024 - American Society of Clinical Oncology Annual Meeting - 1 year(s) ago
Check this out – Top Trials for ASCO 2024 – American Society of Clinical Oncology Annual Meeting
Source: clin.larvol.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/zNsg4yBRuP. @mtmdphd @SuyogCancer @kevinpunie top #asco24 trials with top buzz. Any surprises so far? https://t.co/AvLIEFITtG
-
-
Mashup Score: 2
Check this out – KEYNOTE-585 – Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
Source: clin.larvol.comCategories: General Medicine News, Hem/OncsTweet-
RT @kalpandevi: Trial page for KEYNOTE-585 / NCT03221426 https://t.co/gxeKxTu4I3 via @larvol
-
-
Mashup Score: 1KarMMa-3 - Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) - 1 year(s) ago
Check this out – KarMMa-3 – Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Source: clin.larvol.comCategories: General Medicine News, Hem/OncsTweet-
@HadidiSamer https://t.co/a1BF94g3p2. All data and 200 curated tweets o. KarMMa-3. Would love your feedback (no login needed ) https://t.co/GrYP9rvlqy
-
-
Mashup Score: 1
Check this out – FLAURA2 – A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
Source: clin.larvol.comCategories: General Medicine News, Hem/OncsTweet-
@CharuAggarwalMD @RamalingamMD @JSabari @IASLC @LeciaSequist @JoelNealMD https://t.co/A1QyVvYrL7. Curated data on #FLAURA2. No login needed. Would LOVE feedback on utility and way to improve. Thanks 🙏🏻 https://t.co/BSazpUxTb6
-
-
Mashup Score: 2ASCO-GU 2024 - ASCO-Genitourinary Cancers Symposium 2024 - 1 year(s) ago
Check this out – Top Trials for ASCO-GU 2024 – ASCO-Genitourinary Cancers Symposium 2024
Source: clin.larvol.comCategories: General Medicine News, Hem/OncsTweet-
@TiansterZhang @ASCO @OncoAlert @Uromigos Thanks @TiansterZhang .. and here are the trials that seem to be having the highest pre #GU24 buzz on https://t.co/eZjsM7oqNN https://t.co/2Dqk1YFoh1
-
-
Mashup Score: 2ASCO-GU 2024 - ASCO-Genitourinary Cancers Symposium 2024 - 1 year(s) ago
Check this out – Top Trials for ASCO-GU 2024 – ASCO-Genitourinary Cancers Symposium 2024
Source: clin.larvol.comCategories: General Medicine News, Hem/OncsTweet-
@TiansterZhang @ASCO @OncoAlert @Uromigos Thanks @TiansterZhang .. and here are the trials that seem to be having the highest pre #GU24 buzz on https://t.co/eZjsM7oqNN https://t.co/2Dqk1YFoh1
-
-
Mashup Score: 2ASCO-GU 2024 - ASCO-Genitourinary Cancers Symposium 2024 - 1 year(s) ago
Check this out – Top Trials for ASCO-GU 2024 – ASCO-Genitourinary Cancers Symposium 2024
Source: clin.larvol.comCategories: General Medicine News, Hem/OncsTweet-
@TiansterZhang @ASCO @OncoAlert @Uromigos Thanks @TiansterZhang .. and here are the trials that seem to be having the highest pre #GU24 buzz on https://t.co/eZjsM7oqNN https://t.co/2Dqk1YFoh1
-
@mtmdphd @grpetersen1 @bdermanmd @HadidiSamer @jmikhaelmd @MyelomaTeacher @RahulBanerjeeMD @rajshekharucms @szusmani @End_myeloma @bhemato @MeeraMohanMD @myelomaMD @VincentRK @CyclingDoctor @Amyloid_Planet @MayoMyeloma OncoBuzz so far (https://t.co/F0b1m8s1Hw) https://t.co/zrlfbQEwQT